The company said, “Kestra is increasing its FY26 revenue guidance to $91 million, which would represent growth of 52% compared to FY25. This compares to prior FY26 revenue guidance of $88 million and initial FY26 guidance of $85 million.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KMTS:
- Kestra Medical Technologies Ltd. (KMTS) Q2 Earnings Cheat Sheet
- Kestra Medical Raises $148.4 Million in Public Offering
- Kestra Medical 6.0M share Secondary priced at $23.00
- Midday Fly By: Nvidia invests in Synopsys, U.S. strikes pharma deal with UK
- Kestra Medical announces underwritten public offering of 5.5M shares